An Antimicrobial Blue Light Prototype Device Controls Infected Wounds in a Preclinical Porcine Model.

We developed a translational prototype antimicrobial blue light (ABL) device for treating skin wounds with ABL. Partial-thickness surgical wounds were created in live swine (an animal whose skin is considered the most like human skin), then heavily contaminated and left untreated for 24 hours with methicillin-resistant Staphylococcus aureus (MRSA). ABL treatment stabilized and reduced MRSA infection by greater than 4 orders of magnitude (>99.99%; P < .0001) compared with untreated wounds in the same animal, after only 2 daily treatments. These data support further development of such devices for controlling infection in skin wounds. ABL, with or without concomitant administration of negative pressure, antimicrobials, or photosensitizers, could play an important role in modern wound care by reducing the amount, duration, and cost of antibiotics needed, helping reduce antimicrobial resistance. No such device for treating human cutaneous wounds currently exists. This deserves further development and study.